Ladenburg Thalmann Downgrades United Therapeutics Corp. (UTHR) to Neutral

Go back to Ladenburg Thalmann Downgrades United Therapeutics Corp. (UTHR) to Neutral

United Therapeutics (UTHR) Misses Q1 EPS by 19c

April 28, 2016 9:25 AM EDT

United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.02, $0.19 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $369 million versus the consensus estimate of $397.42 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

... More

United Therapeutics' (UTHR) CO-CEO and COO to Step Down

April 28, 2016 9:23 AM EDT

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Roger Jeffs, Ph.D. has stepped down as the company's President and Co-Chief Executive Officer and David Zaccardelli, Pharm.D. has stepped down as the company's Executive Vice President and Chief Operating Officer. These departures will become effective June 26, 2016. In addition, Dr. Jeffs will not stand for re-election to the company's Board of Directors when his current term expires at the 2016 Annual Meeting of Shareholders, which is to be held on June 21, 2016. Dr. Jeffs will become a Senior Advisor to the company.

Michael Benkowitz, the company's current... More